Lomitapide as a Potential Estrogen Receptor Inhibitor: A Computational Drug Repurposing Study

Abstract

Objective: Estrogen receptor (ER) inhibitors have significant therapeutic potential for hormone-dependent cancers and related disorders. Tamoxifen, a well-known selective estrogen receptor modulator, has been widely used as adjuvant therapy for estrogen receptor-positive breast cancer. However, tamoxifen may exhibit a tendency to develop resistance with prolonged usage and particularly elevate the risk of uterine cancer. Therefore, there is a need for the discovery and development of new ER modulators or inhibitors. In this study, we identified potential estrogen receptor inhibitors through computational drug repositioning. Methods: A set of 2048 compounds, encompassing FDA-approved drugs and active metabolites, were subjected to molecular docking, molecular dynamics simulations, and free energy calculations to evaluate their interaction with estrogen receptor α (ERα). Results: Among the compounds evaluated, conivaptan, atogepant, and lomitapide exhibited the highest affinities for ERα. Lomitapide displayed a superior docking score (-12 kcal/mol) compared to the established ER inhibitor, tamoxifen (-10 kcal/mol). Further investigation using molecular dynamics simulations and free energy calculations disclosed lomitapide's heightened binding affinity of -380.727 kJ/mol, surpassing tamoxifen's binding affinity of -352.029 kJ/mol. Conclusion: This comprehensive computational exploration underscores lomitapide's potential as a compelling candidate with an envisaged stronger estrogen receptor affinity than the acknowledged standard, tamoxifen. To validate lomitapide's promise as a novel ER inhibitor, essential in vitro and in vivo studies are suggested. These investigations will provide essential insights into lomitapide's reposition in addressing the challenges tied to hormone-dependent cancers and associated maladies.

Keywords

• Estrogen Receptor Antagonists
• Drug Repositioning
• Lomitapide
• Tamoxifen
• Molecular Docking
• Molecular Dynamics Simulation

References

1. Hall JM, Couse JF, Korach KS. The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling. J Biol Chem. 2001;276(40). doi:10.1074/jbc.R100029200
2. Srinivasan S, Nawaz Z. Molecular biology of estrogen receptor action. In: Hormones, Brain and Behavior Online.; 2009. doi:10.1016/B978-008088783-8.00035-8
3. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1-24. doi:10.1016/j.pharmthera.2017.12.012
4. Shagufta, Ahmad I. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018;143:515-531. doi:10.1016/j.ejmech.2017.11.056
5. Visvanathan K, Fabian CJ, Bantug E, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472
6. Dar H, Johansson A, Nordenskjöld A, et al. Assessment of 25-Year Survival of Women with Estrogen Receptor-Positive/ ERBB2 -Negative Breast Cancer Treated with and without Tamoxifen Therapy: A Secondary Analysis of Data from the Stockholm Tamoxifen Randomized Clinical Trial. JAMA Netw Open. 2021;4(6). doi:10.1001/jamanetworkopen.2021.14904
7. Rosso R, D’Alonzo M, Bounous VE, et al. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Curr Oncol. 2023;30(2). doi:10.3390/curroncol30020112
8. Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3). doi:10.1007/s10549-018-05086-8

9. Zhang K, Jiang K, Hong R, et al. Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer. PeerJ. 2020;8. doi:10.7717/peerj.10468
10. Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr Protoc Bioinforma. 2016;54(1):5-6.
11. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-1612. doi:10.1002/jcc.20084
12. Douguet D. Data sets representative of the structures and experimental properties of FDA-approved drugs. ACS Med Chem Lett. 2018;9(3):204-209.
13. Samdani A, Vetrivel U. POAP: A GNU parallel based multithreaded pipeline of open babel and AutoDock suite for boosted high throughput virtual screening. Comput Biol Chem. 2018;74:39-48.
14. Alhossary A, Handoko SD, Mu Y, Kwoh C-K. Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinformatics. 2015;31(13):2214-2216.
15. Huey R, Morris GM, Forli S. Using AutoDock 4 and AutoDock vina with AutoDockTools: a tutorial. Scripps Res Inst Mol Graph Lab. 2012;10550(92037):1000.
16. Goddard TD, Huang CC, Meng EC, et al. UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci. 2018;27(1):14-25.
17. Bell EW, Zhang Y. DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. J Cheminform. 2019;11(1):1-9.
18. Sousa da Silva AW, Vranken WF. ACPYPE-Antechamber python parser interface. BMC Res Notes. 2012;5:1-8.
19. Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation. J Comput Chem. 2002;23(16):1623-1641.
20. Abraham MJ, Murtola T, Schulz R, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19-25.
21. Lindorff‐Larsen K, Piana S, Palmo K, et al. Improved side‐chain torsion potentials for the Amber ff99SB protein force field. Proteins Struct Funct Bioinforma. 2010;78(8):1950-1958.
22. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: A linear constraint solver for molecular simulations. J Comput Chem. 1997;18(12):1463-1472.
23. Berendsen HJC, Postma JPM van, Van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81(8):3684-3690.
24. Martoňák R, Laio A, Parrinello M. Predicting Crystal Structures: The Parrinello-Rahman Method Revisited. Phys Rev Lett. 2003;90(7):4. doi:10.1103/PhysRevLett.90.075503
25. Kumari R, Kumar R, Consortium OSDD, Lynn A. g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951-1962.
26. Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen Receptor Function: Impact on the Human Endometrium. Front Endocrinol (Lausanne). 2022;13. doi:10.3389/fendo.2022.827724
27. Min J, Nwachukwu JC, Min CK, et al. Dual-mechanism estrogen receptor inhibitors. Proc Natl Acad Sci U S A. 2021;118(35). doi:10.1073/pnas.2101657118
28. Stefanutti C. Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia. Curr Atheroscler Rep. 2020;22(8). doi:10.1007/s11883-020-00858-4
29. Sen P, Kandasamy T, Ghosh SS. Multi-targeting TACE/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide. Cell Signal. 2023;102. doi:10.1016/j.cellsig.2022.110529
30. Lee B, Park SJ, Lee S, et al. Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR. Cell Death Dis. 2022;13(7):603. doi:10.1038/s41419-022-05039-6
31. Wang Y, Zhang S, He H, et al. Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell Death Discov. 2023;9(1). doi:10.1038/s41420-023-01359-4
32. Zuo Q, Liao L, Yao ZT, et al. Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK/Beclin1-mediated autophagy. Cancer Lett. 2021;521. doi:10.1016/j.canlet.2021.09.010
33. TilakVijay J, Babu KV, Uma A. Virtual screening of novel compounds as potential ER-alpha inhibitors. Bioinformation. 2019;15(5):321. doi:10.6026/97320630015321
34. Li-Ng M, Verbalis JG. Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid. 2009;4. doi:10.2147/ce.s5997
35. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007;15(12):1341-1347. doi:10.1007/S00520-007-0309-9/FIGURES/2
36. Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin cancer Res. 2013;19(13):3353-3359.
37. Dou D, Ji Y, Zheng J, et al. A New Role for Conivaptan in Ulcerative Colitis in Mice: Inhibiting Differentiation of CD4+ T Cells into Th1 Cells. Dig Dis Sci. Published online 2022:1-10.
38. Deeks ED. Atogepant: First Approval. Drugs. 2022;82(1):65-70. doi:10.1007/S40265-021-01644-5
39. Ankrom W, Xu J, Vallee M, et al. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants. J Clin Pharmacol. 2020;60(9):1157-1165. doi:10.1002/jcph.1610
40. Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18(12):1261-1268.
41. Khan MI, Waguespack SG, Ahmed I. Recent advances in the management of hyponatremia in cancer patients. J Cancer Metastasis Treat. 2019;5:71.